These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 10375390)

  • 1. Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
    Gibson CM; Moynihan JL; Al-Mousa EN; Campsey M; Gandhi R; Murphy S; Mattson S; Ryan KA; Mesley R; Swanson J; Arshad MN; Marble SJ
    J Thromb Thrombolysis; 1999 Jun; 7(3):287-302. PubMed ID: 10375390
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
    Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Bhatt DL; Topol EJ
    JAMA; 2000 Sep; 284(12):1549-58. PubMed ID: 11000650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy of acute coronary syndrome with glycoprotein IIb/IIIa antagonists].
    Araujo R; Agustí A
    Med Clin (Barc); 2000 Oct; 115(11):435-7. PubMed ID: 11093849
    [No Abstract]   [Full Text] [Related]  

  • 5. GP IIb/IIIa inhibitors in coronary artery disease management: what the latest trials tell us.
    Chew DP; Moliterno DJ
    Cleve Clin J Med; 2001 Dec; 68(12):1017-23. PubMed ID: 11765119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention.
    Kereiakes DJ; Broderick TM; Roth EM; Whang D; Shimshak T; Runyon JP; Hattemer C; Schneider J; Lacock P; Mueller M; Abbottsmith CW
    Am J Cardiol; 1999 Aug; 84(4):391-5. PubMed ID: 10468074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing.
    Hobbach HP; Schuster P
    Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy.
    Wu KK; Willerson JT
    Circulation; 2001 May; 103(21):2528-30. PubMed ID: 11382717
    [No Abstract]   [Full Text] [Related]  

  • 9. Glycoprotein IIb/IIIa antagonists and low-molecular weight heparin in acute coronary syndromes.
    Vernon SM
    Cardiol Clin; 2001 May; 19(2):235-52, vi. PubMed ID: 11407108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
    Gurm HS; Tamhane U; Meier P; Grossman PM; Chetcuti S; Bates ER
    Circ Cardiovasc Interv; 2009 Jun; 2(3):230-6. PubMed ID: 20031720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Roe MT; Sapp SK; Lincoff AM
    Cleve Clin J Med; 2000 Feb; 67(2):131-40. PubMed ID: 10680279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease.
    Berkowitz SD
    Haemostasis; 2000; 30 Suppl 3():27-43. PubMed ID: 11182626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment.
    Tcheng JE
    Am J Cardiol; 1999 May; 83(9A):7E-11E. PubMed ID: 10357575
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention.
    Herrmann HC; Swierkosz TA; Kapoor S; Tardiff DC; DiBattiste PM; Hirshfeld JW; Klugherz BD; Kolansky DM; Magness K; Valettas N; Wilensky RL
    Am J Cardiol; 2002 Jun; 89(11):1293-7. PubMed ID: 12031731
    [No Abstract]   [Full Text] [Related]  

  • 16. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
    Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
    Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
    Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
    Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
    Lincoff AM; Califf RM; Topol EJ
    J Am Coll Cardiol; 2000 Apr; 35(5):1103-15. PubMed ID: 10758948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes.
    Tcheng JE
    Am Heart J; 1999 Oct; 138(4 Pt 2):261-2. PubMed ID: 10502231
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.